Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsored by: |
AstraZeneca |
---|---|
Information provided by: | AstraZeneca |
ClinicalTrials.gov Identifier: | NCT00726362 |
The primary objective is to survey the efficacy of various commercially available statins (a class of lipid-lowering agents, for example, rosuvastatin, atorvastatin, simvastatin, lovastatin, pravastatin and fluvastatin) under local clinical practice in treating patients with hyperlipidemia. Surveillance data (Lipid Profile) will be collected during course of usual clinical practice or captured upon its availability.
Condition |
---|
Hyperlipidemias |
Study Type: | Observational |
Study Design: | Cohort, Prospective |
Official Title: | To Explore the Treatment Effect of Various Commercially Available Statins on Patients With Hyperlipidemia |
Estimated Enrollment: | 3300 |
Study Start Date: | September 2007 |
Estimated Study Completion Date: | October 2009 |
Groups/Cohorts |
---|
1
patients with hyperlipidemia newly initiating a statin; or switched from current therapy to a statin, or require dosage adjustment for statin
|
Ages Eligible for Study: | 20 Years and older |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Sampling Method: | Probability Sample |
based on regular practice and judged by physicians, patients with hyperlipidemia who need to start prescribed with a statin; or to switch from current therapy to a statin, or require dosage adjustment for statin
Inclusion Criteria:
Exclusion Criteria:
Contact: AstraZeneca Taiwan Clinical Study Information | +886-2-2378-2390 | jade.lien@astrazeneca.com |
Taiwan | |
Research Site | Recruiting |
Changhua, Taiwan | |
Research Site | Recruiting |
Hualien, Taiwan | |
Research Site | Recruiting |
Kaohsiung, Taiwan | |
Research Site | Recruiting |
Pingtung, Taiwan | |
Research Site | Recruiting |
Yun-Lin, Taiwan | |
Research Site | Recruiting |
Tainan, Taiwan | |
Research Site | Recruiting |
Taipei, Taiwan | |
Research Site | Recruiting |
Taichung, Taiwan |
Principal Investigator: | Wen-Ter Lai, MD | Kaohsiung Medical University |
Responsible Party: | AstraZeneca Pharmaceuticals ( William Huang/Medical Director ) |
Study ID Numbers: | NIS-CTW-CRE-2007/1 |
Study First Received: | July 29, 2008 |
Last Updated: | July 29, 2008 |
ClinicalTrials.gov Identifier: | NCT00726362 |
Health Authority: | Taiwan: Institutional Review Board |
Statin LDL-C |
Metabolic Diseases Hyperlipidemias Metabolic disorder Dyslipidemias Lipid Metabolism Disorders |